

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15552 A1

(51) International Patent Classification⁷: A23L 1/30, A61K 31/575, C11C 3/00, C07J 9/00

(21) International Application Number: PCT/CA00/01011

(22) International Filing Date: 30 August 2000 (30.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/385,834 30 August 1999 (30.08.1999) US

(71) Applicant (for all designated States except US): OCEAN NUTRITION CANADA LTD. [CA/CA]; 1721 Lower Water Street, Halifax, Nova Scotia B4A 3Z7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WRIGHT, Jeffrey, L., C. [CA/US]; Center for Marine Science, University of North Carolina, Masonboro Loop Road, Wilmington, NC 28409 (US). KRALOVEC, Jaroslav, A. [CA/CA]; 11 Berkshire Close, Halifax, Nova Scotia B3S 1H4 (CA).

(74) Agents: WHEELER, Michael, E. et al.; Smart & Biggar, 900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A NUTRITIONAL SUPPLEMENT FOR LOWERING SERUM TRIGLYCERIDE AND CHOLESTEROL LEVELS

(57) Abstract: Triglycerides and cholesterol in the bloodstream are important factors in the development of cardiovascular disease. The present invention discloses a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, for lowering cholesterol and triglyceride levels in the bloodstream of a subject. Preferably, the sterol and omega-3 fatty acid are together in the form of an ester.

BEST AVAILABLE COPY

WO 01/15552 A1

**A Nutritional Supplement For Lowering Serum Triglyceride and
Cholesterol Levels**

Field of the Invention

The invention relates to control of cholesterol and
5 triglyceride levels in mammals, particularly humans.

Background of the Invention

Serum cholesterol and serum triglyceride levels are
important factors in the development of cardiovascular disease.
In many clinical studies there is a positive correlation
10 between plasma triglycerides and the incidence of
cardiovascular disease [1]. Elevated plasma triglyceride level
is frequently associated with other atherogenic factors
including elevated low-density lipoprotein (LDL)-cholesterol,
reduced high-density lipoprotein (HDL)-cholesterol, and small
15 LDL particles [2, 3]. There is growing acceptance that
triglycerides act in a synergistic fashion with these other
lipid risk factors to increase the incidence of cardiovascular
disease [4, 5]. Hypertriglyceridemia usually occurs because
of insulin resistance, which leads to overproduction of very
20 low-density lipoproteins (VLDL) by the liver [3]. Treatment
involves lifestyle changes to decrease body weight and to
increase physical activity, both of which improve insulin
sensitivity. Drug therapy to lower triglycerides involves the
use of fibrates or nicotinic acid [6].

25 A number of clinical studies convincingly establish
plasma cholesterol and LDL-cholesterol as independent risk
factors for coronary heart disease [7]. Pharmacological
agents, called statins, lower total plasma cholesterol by
inhibiting the synthesis of cholesterol by the liver. The

statins reduce the morbidity and mortality rate from cardiovascular disease in high risk, hypercholesterolemic patients [8, 9], but also in persons who exhibit "average" cholesterol levels [10]. Another approach is to interfere with the intestinal absorption of cholesterol. Certain phytosterols (plant sterols) such as stigmasterol and β -sitosterol lower serum cholesterol act by inhibiting absorption of both dietary and biliary cholesterol from the small intestine [11].

With respect to the most appropriate form of phytosterols for lowering serum cholesterol, some reports indicate that free phytosterols reduce serum cholesterol in animals and humans [12, 13]. However, there is also evidence to indicate that a sterol esterified with a fatty acid may be more effective [14]. Trials show that phytosterol esters of plant fatty acids obtained from canola oil, when incorporated into food such as margarine or mayonnaise, lower total cholesterol and LDL-cholesterol levels by about 10 and 15 percent, respectively [15, 16]. United States Patent No. 5,502,045 (Miettinen et al., issued March 26, 1996) discloses the use of sitostanol esters of canola oil to lower serum cholesterol. Benecol™ (Raisio Benecol Ltd., Raisio, Finland), a margarine that contains such compounds, is now on the market.

The mechanism by which phytosterols or phytosterol esters inhibit absorption of dietary cholesterol by the digestive tract is not fully understood but may involve competitive inhibition of cholesterol uptake from the intestinal lumen or inhibition of cholesterol esterification in the intestinal mucosa [12]. It is known that phytosterols themselves are only poorly absorbed. Vanhanen et al. [17] report that phytosterol esters may also be poorly absorbed by

the intestinal tract, based on postprandial measurements of β -sitosterol in plasma. A direct measure of phytosterol ester uptake by the digestive tract has not been reported.

When phytosterols are esterified with fatty acids from plant sources such as canola, the long-chain polyunsaturated fatty acids (LCPUFAs) that are incorporated are predominantly of the omega-6 series. Omega-6 fatty acids do not affect plasma triglycerides. Research to date on fatty acid esters of sterols has focused only on the efficacy of the sterol in lowering cholesterol.

Summary of the Invention

The present invention provides a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, for lowering cholesterol and triglyceride levels in the bloodstream of a subject.

The present invention also provides a method of lowering cholesterol and triglyceride levels in the bloodstream of a subject, the method including the step of administration of an effective amount of a nutritional supplement comprising a sterol and an omega-3 fatty acid, or an ester thereof, to a subject.

The present invention also provides the use of the nutritional supplement defined herein for lowering cholesterol and triglyceride levels in the bloodstream of a subject.

The subject is preferably a mammal, more preferably a human.

The present invention further provides a foodstuff composition comprising the nutritional supplement defined

herein and a foodstuff, the nutritional value of the foodstuff being enhanced by incorporation of the nutritional supplement defined herein.

The present invention further provides the use of the
5 nutritional supplement defined herein in the manufacture of a foodstuff composition.

The present invention further provides a process for preparing the nutritional supplement as defined herein, which comprises the step of reacting a sterol with an omega-3 fatty
10 acid, or an ester thereof, in the presence of a base.

Base catalysts were found to be successful in the transesterification (or interesterification) process of the invention. Such a reaction is advantageous given the availability of esterified omega-3 fatty acid starting
15 material, for example from fish oil. In addition, acidic catalysts were found to be ineffective in the transesterification of interest.

Sterols are not very soluble in lipid, which complicates their use in lipid-based foods. A mixture of a
20 sterol and a free omega-3 fatty acid, which typically forms a paste at a molar ratio of 1:1, may be used. If a mixture is used, the omega-3 fatty acid can be a free acid or can be in ester form, preferably a succinimidyl, triglyceride, (C₃-C₁₂)cycloalkyl or (C₁-C₈)alkyl ester, more preferably an
25 ethyl ester. In the mixture, the molar ratio range of omega-3 fatty acid, or an ester thereof, to sterol should be about 0.5 to 8, preferably 0.76 to 6.4, more preferably 1 to 2.


Preferably, the sterol and the omega-3 fatty acid are together in the form of an ester. The sterol esters of the

present invention are highly fat-soluble and represent a bifunctional species, since they lower both serum cholesterol and serum triglyceride levels in the bloodstream.

Detailed Description of the Preferred Embodiments




5 The sterols used to prepare the nutritional supplement of the present invention are preferably phytosterols, and preferably have a perhydrocyclopentanophenanthrene ring system as shown below in the compound of formula I:

10



15 wherein the dashed line is a single or double bond and R is a (C₁-C₁₀)alkyl, substituted (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl or substituted (C₂-C₁₀)alkenyl group.


 In the present application, the term "sterols" includes sterols in reduced form (stanols), preferably
20 β-sitostanol or fucostanol (reduced fucosterol).



One or more sterols can be used to prepare the nutritional supplement. The term "phytosterols" includes sterols from terrestrial or marine plants, seaweed, microalgae, etc. Preferably, the sterol is stigmasterol, sitosterol,
 5 fucosterol, β -sitostanol or fucostanol.


Fucosterol is abundant in brown algae. Prior to esterification with the omega-3 fatty acid, fucosterol can be reduced to fucostanol. Preferably, the reduction is carried out using hydrogen gas in the presence of a suitable catalyst
 10 such as palladium on charcoal (Pd/C), but other reduction processes that ultimately yield a food-quality ester, after purification if necessary, may be used.


The nutritional supplement of the present invention comprises one or more omega-3 fatty acids, and is preferably an
 15 ester of an acid of the formula:



20 wherein R^1 is a (C_3 - C_{40})alkenylene group comprising at least one double bond, more preferably 2 to 5 double bonds. More preferably, the omega-3 fatty acid is stearidonic acid 18:4 ω 3 (SA), eicosapentaenoic acid 20:5 ω 3 (EPA) or docosahexaenoic acid 22:6 ω 3 (DHA).

25





docosahexaenoic acid

5 Omega-3 fatty acids, such as EPA and DHA, are long-chain polyunsaturated fatty acids (LCPUFAs) that are abundant in oily fish such as menhaden, salmon, tuna, and sardine, as well as in certain plants and microbes, such as particular fungi and microalgae. The preferred source of
10 omega-3 fatty acids for the present invention is fish oil, more preferably a highly refined fish oil concentrate having approximately 65% omega-3 fatty acid content which is predominantly EPA and DHA in the form of triglyceride esters. These triglycerides are preferably converted to lower alkyl
15 esters, such as methyl, ethyl or propyl esters, by known methods and used in an esterification with a sterol to form esters, which can be further purified if necessary, for use as nutritional supplements.

 The cardiovascular effects of dietary fish oils have
20 long been recognized [18, 19]. Omega-3 fatty acids lower plasma triglyceride concentrations principally by inhibiting synthesis of triacylglycerol and VLDL by the liver [20]. In addition, omega-3 fatty acids are anti-thrombotic and are protective against cardiac arrhythmias [21]. The benefits of
25 fish oil consumption are illustrated by the finding of the Diet and Reinfarction Trial (DART) which showed a reduction of 29% in the overall mortality in survivors of a first myocardial infarction who consumed fish rich in omega-3 fatty acids at least twice weekly [22]. Two recent studies demonstrate the

efficacy of omega-3 fatty acid supplementation. In a randomized, double-blind, placebo-controlled trial patients with coronary artery disease who ingested a 1.5g/day fish oil supplement (55% EPA and DHA) for two years had less progression and more regression of their disease based on coronary angiography compared to patients ingesting the placebo [23]. In the GISSI- Prevenzione trial, omega-3 fatty acid supplements in patients who had myocardial infarction reduced cardiovascular death by 30% [24]. Although omega-3 fatty acids are anti-atherogenic, they do not lower plasma cholesterol and in some incidences may slightly increase LDL-cholesterol [25]. Safety and toxicological studies spanning several years have shown that fish oils are safe to consume. Recently, fatty acids such as the omega-3 fatty acids from fish oil were granted GRAS (Generally Regarded As Safe) status in the United States, which permits their addition to foods low in long-chain polyunsaturated fatty acids. The typical North American diet contains about 0.15 grams omega-3 fatty acids whereas Inuit may ingest up to 10 grams of omega-3 fatty acids daily. A daily intake of 2 to 3 grams of omega-3 fatty acids has consistently been shown to lower plasma triglycerides [18]. Therefore, a suitable daily intake of omega-3 fatty acid in the present invention is about 0.1 to about 10 grams, preferably about 2 to about 3 grams, but clearly greater amounts can be tolerated, and may be beneficial.

Phytosterols are considered safe for human consumption. A typical daily intake in North America is about 100 to 300 milligrams. However, a dose of greater than 3 grams of the phytosterol esters are required to have significant impact on plasma cholesterol levels [13]. Such doses are safe with no known side effects. In the present invention, a

preferred daily intake of phytosterol is about 2 to about 3 grams.

Phytosterol esters prepared using fish oil as the source of omega-3 fatty acids contain a significant amount of EPA and DHA. Such esters can simultaneously reduce serum cholesterol and serum triglyceride levels. The triglyceride-lowering ability of the omega-3 fatty acid component of the ester is dependent on its entry into the circulatory system. A lipid esterase in the intestinal lumen may be responsible for release of the omega-3 fatty acid from the phytosterol, which would make both species available for uptake into the circulatory system. There is a non-specific lipid esterase, secreted into the intestinal lumen during digestion that is active against a variety of molecular species including cholesterol esters, monoglycerides, and esters of vitamin A [26].

At least one edible additive, such as listed below, can be included for consumption with the nutritional supplement of the invention and may have, for example, antioxidant, dispersant, antimicrobial, or solubilizing properties. A suitable antioxidant is, for example, vitamin C, vitamin E or rosemary extract. A suitable dispersant is, for example, lecithin, an alkyl polyglycoside, polysorbate 80 or sodium lauryl sulfate. A suitable antimicrobial is, for example, sodium sulfite or sodium benzoate. A suitable solubilizing agent is, for example, a vegetable oil such as sunflower oil, coconut oil, and the like, or mono-, di- or tri-glycerides.

Additives include vitamins such as vitamin A (retinol, retinyl palmitate or retinol acetate), vitamin B1 (thiamin, thiamin hydrochloride or thiamin mononitrate),

vitamin B2 (riboflavin), vitamin B3 (niacin, nicotinic acid or niacinamide), vitamin B5 (pantothenic acid, calcium pantothenate, d-panthenol or d-calcium pantothenate), vitamin B6 (pyridoxine, pyridoxal, pyridoxamine or pyridoxine hydrochloride), vitamin B12 (cobalamin or cyanocobalamin), folic acid, folate, folacin, vitamin H (biotin), vitamin C (ascorbic acid, sodium ascorbate, calcium ascorbate or ascorbyl palmitate), vitamin D (cholecalciferol, calciferol or ergocalciferol), vitamin E (d-alpha-tocopherol, d-beta-tocopherol, d-gamma-tocopherol, d-delta-tocopherol or d-alpha-tocopheryl acetate) and vitamin K (phylloquinone or phytonadione).

Other additives include minerals such as boron (sodium tetraborate decahydrate), calcium (calcium carbonate, calcium caseinate, calcium citrate, calcium gluconate, calcium lactate, calcium phosphate, dibasic calcium phosphate or tribasic calcium phosphate), chromium (GTF chromium from yeast, chromium acetate, chromium chloride, chromium trichloride and chromium picolinate) copper (copper gluconate or copper sulfate), fluorine (fluoride and calcium fluoride), iodine (potassium iodide), iron (ferrous fumarate, ferrous gluconate or ferrous sulfate), magnesium (magnesium carbonate, magnesium gluconate, magnesium hydroxide or magnesium oxide), manganese (manganese gluconate and manganese sulfate), molybdenum (sodium molybdate), phosphorus (dibasic calcium phosphate, sodium phosphate), potassium (potassium aspartate, potassium citrate, potassium chloride or potassium gluconate), selenium (sodium selenite or selenium from yeast), silicon (sodium metasilicate), sodium (sodium chloride), strontium, vanadium (vanadium sulfate) and zinc (zinc acetate, zinc citrate, zinc gluconate or zinc sulfate).

Other additives include amino acids, peptides, and related molecules such as alanine, arginine, asparagine, aspartic acid, carnitine, citrulline, cysteine, cystine, dimethylglycine, gamma-aminobutyric acid, glutamic acid, glutamine, glutathione, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, taurine, threonine, tryptophan, tyrosine and valine.

Other additives include animal extracts such as cod liver oil, marine lipids, shark cartilage, oyster shell, bee pollen and d-glucosamine sulfate.

Other additives include unsaturated free fatty acids such as γ -linoleic, arachidonic and α -linolenic acid, which may be in an ester (e.g. ethyl ester or triglyceride) form.

Other additives include herbs and plant extracts such as kelp, pectin, Spirulina, fiber, lecithin, wheat germ oil, safflower seed oil, flax seed, evening primrose, borage oil, blackcurrant, pumpkin seed oil, grape extract, grape seed extract, bark extract, pine bark extract, French maritime pine bark extract, muira puama extract, fennel seed extract, dong quai extract, chaste tree berry extract, alfalfa, saw palmetto berry extract, green tea extracts, angelica, catnip, cayenne, comfrey, garlic, ginger, ginseng, goldenseal, juniper berries, licorice, olive oil, parsley, peppermint, rosemary extract, valerian, white willow, yellow dock and yerba mate.

Other additives include enzymes such as amylase, protease, lipase and papain as well as miscellaneous substances such as menaquinone, choline (choline bitartrate), inositol, carotenoids (beta-carotene, alpha-carotene, zeaxanthin, cryptoxanthin or lutein), para-aminobenzoic acid, betaine HCl,

free omega-3 fatty acids and their esters, thiotic acid (alpha-lipoic acid), 1,2-dithiolane-3-pentanoic acid, 1,2-dithiolane-3-valeric acid, alkyl polyglycosides, polysorbate 80, sodium lauryl sulfate, flavanoids, flavanones, flavones, flavonols, isoflavones, proanthocyanidins, oligomeric proanthocyanidins, vitamin A aldehyde, a mixture of the components of vitamin A₂, the D Vitamins (D₁, D₂, D₃ and D₄) which can be treated as a mixture, ascorbyl palmitate and vitamin K₂.

The nutritional supplement of the invention is typically a viscous oil and can be added to a foodstuff composition during processing of the foodstuff. Such a foodstuff composition is often referred to as a functional food, and can be any food that will tolerate the physicochemical properties of the nutritional supplement, for example, margarine, cooking oil, shortening or mayonnaise. It can also be packaged for consumption in softgel, capsule, tablet or liquid form. It can be supplied in edible polysaccharide gums, for example carrageenan, locust bean gum, guar, tragacanth, cellulose and carboxymethylcellulose.

The nutritional supplement can also be microencapsulated. Microencapsulation can be carried out, for example, using a gelatin such as bovine gelatin in a co-extrusion process, prior to processing into a foodstuff composition, for example baked goods, candy, margarines and spreads, ice cream, yogurts, frozen desserts, cake mixes and pudding mixes. The packaging of the nutritional supplement should preferably provide physical protection from such effects as pH, particularly basic conditions, oxidation and degradation by light. This latter effect can be minimized for example by changing the mesh size of the microencapsulation or inclusion

of a suitable dye. The nutritional supplement can also be stored in a light-opaque container to minimize photodegradation.

The example below describes synthesis of an ester of the invention. The ester linkage can be formed according to known methods, such as by esterification of free fatty acids by sterols or stanols under acid catalysis (US Patent No. 5,892,068: Higgins III, issued April 6, 1999). Preferably, however, a base is used as a catalyst to promote transesterification. More preferably, the base is a metal (C_1 - C_{10})alkoxide, even more preferably sodium methoxide or ethoxide. Conveniently, the reactants are heated to a temperature of about 100°C to about 200°C with stirring, preferably under reduced pressure, for about 30 minutes to about 4 hours. The base is then added and the mixture conveniently stirred at a temperature of about 100°C to about 200°C under reduced pressure for about 30 minutes to about 36 hours. Alternatively, the starting ester is heated to a temperature of about 100°C to about 200°C with stirring, preferably under reduced pressure, for about 30 minutes to about 4 hours. The base dispersed in the phytosterol is then added and the mixture conveniently stirred at a temperature of about 100°C to about 200°C under reduced pressure for about 30 minutes to about 36 hours. The ester that is formed can be further purified if necessary for use as a nutritional supplement.

The further purification is preferably carried out by precipitation and extraction, preferably sequentially, using two immiscible solvents. Unreacted sterol is precipitated by addition of a suitable non-polar solvent and filtered off. A suitable non-polar solvent can be an aliphatic liquid such as a

liquid alkane, preferably pentane, hexane, heptane, octane, isooctane or dodesane, more preferably hexane. Corresponding fluoroalkanes can also be used. The non-polar solvent can also be an aromatic solvent such as benzene or toluene, or an other
5 solvent of similar polarity such as carbon tetrachloride or methyl-tert-butyl ether.

The filtrate is then extracted by a suitable extraction solvent to remove unreacted omega-3 fatty acid-containing material. The extraction solvent is preferably a
10 polar solvent such as methanol, ethanol or ethylene glycol dimethyl ether (monoglyme), more preferably methanol. Certain dipolar aprotic solvents, such as N,N-dimethyl formamide (DMF) or dimethylsulfoxide (DMSO), can also be used.

Example 1

15 Synthesis of Stigmasterol/Omega-3 Fatty Acid Esters.

(A) A mixture of dry stigmasterol (3 g, 7.27 mmol) and a highly concentrated mixture of EPA and DHA omega-3 fatty acids in ethyl ester form (EPAXTM 5500, ProNova; 4.3 g, 12.6 mmol) were heated while being stirred magnetically at 140 to
20 145°C for 2 hours under vacuum (5 mm). Subsequently the vacuum was disconnected and powdered sodium methoxide (40 mg, 0.75 mmol) was added quickly in one portion. The vacuum was connected immediately and the mixture was stirred at 140 to 145°C for an additional 4 hours. Hexane (25 mL) was added to
25 precipitate the residual stigmasterol and the mixture was centrifuged for 5 minutes at 15,000 g (0°C), the supernatant was removed and the pellet was washed again with 5 mL of hexane. The remaining precipitate was centrifuged off and the supernatants combined. The organic phase was washed with water

(5 mL), dried over sodium sulfate and the solvent removed under reduced pressure. TLC (hexane/diethylether/acetic acid (90:10:1), R_f 0.71. The yield was 5.9 g (85%). The ester product was a viscous oil.

- 5 When the experiment was repeated using freshly made sodium ethoxide, almost the same level of conversion was obtained as with sodium methoxide. However, this was not seen with commercially available sodium ethoxide, which performed more poorly than sodium methoxide.

10 Synthesis of Stigmasterol/Omega-3 Fatty Acid Esters

- (B) A highly concentrated mixture of EPA and DHA omega-3 fatty acids in ethyl ester form (EPAX™ 5500 EE, BioNova; 221 g, 649 mmol) was heated while being stirred magnetically at 140 to 145°C for 2 hours under vacuum (5 mm). A
- 15 well dispersed mixture of dry stigmasterol (268g, 649 mmol) and sodium methoxide (40 mg, 0.75 mmol) was added portionwise within 1 hour and the mixture was stirred at 170 to 175°C for an additional 21 hours. The reaction mixture was liberated from
- 20 unreacted material either by column chromatography (2% diethylether in hexane on silicagel) or by a sequential extraction using two immiscible solvents. The unreacted stigmasterol was precipitated upon addition of hexane and the solution was then filtered. The filtrate was extracted with
- 25 methanol to remove unreacted starting oil material. TLC (hexane/diethylether/acetic acid (90:10:1) gave an R_f equal to 0.71. The yield was 434 g (70 %). The ester product was a viscous oil.

When the experiment was repeated using freshly made sodium ethoxide, almost the same level of conversion was

obtained as with sodium methoxide. However, this was not seen with commercially available sodium ethoxide, which performed more poorly than sodium methoxide.

The procedure works also from a concentrated mixture of EPA and DHA omega-3 fatty acids in triglyceride form (EPAX™ 5500 TG, BioNova) with a similar yield of final product.

Example 2

The effect of a phytosterol-fish oil ester-containing diet on plasma lipid levels in guinea pigs.

Guinea pigs were chosen for this project, as their blood lipid profiles and responses to dietary manipulation more closely resemble those of humans than do more commonly used laboratory rodents. Two groups of eight guinea pigs each were fed a standard, non-purified guinea pig chow (Prolab guinea pig 5P18, PMI Nutrition International, Inc., Brentwood, MO). Baseline values for blood lipids were determined and then the animals were placed on a control diet (Group 1) or a phytosterol-fish oil ester-containing diet (Group 2).

Phytosterol-fish oil esters were prepared as described in Example 1 and mixed 5:1 with corn oil. This was incorporated into crushed chow to give a concentration of phytosterol-fish oil esters of 2.5% (w/w). Control diet was prepared using an equivalent amount of corn oil. Both control and test diets were supplemented with 0.08% cholesterol. The chow was re-pelleted using a Hobart extruder. Food was stored in sealed plastic bags with nitrogen purging at -20°C in the dark. Fresh food was prepared each week.

Blood samples were collected from each animal after 2 and 4 weeks for determination of plasma lipids (total cholesterol, HDL-cholesterol, non-HDL-cholesterol, and triacylglycerols).

5 Guinea pigs fed phytosterol-fish oil esters (2.5% g/100 gram diet) had significantly lower levels of plasma total cholesterol and triacylglycerol compared to control fed animals after 4 weeks of feeding (Table 1). At this time, plasma cholesterol and triacylglycerols were 36% and 29% lower in the
10 treatment group. A statistically significant effect of phytosterol-fish oil esters on cholesterol was also evident after 2 weeks where the reduction was 30% compared to the control value. The changes in cholesterol level could be completely explained by changes in the amount of non-high
15 density lipoprotein (HDL)-cholesterol (Table 2). Non-HDL cholesterol was 30% and 38% lower in the phytosterol-fish oil ester-fed group at 2 and 4 weeks, respectively, whereas there were no differences in HDL-cholesterol.

These results illustrate the ability of dietary
20 phytosterol-fish oil esters to reduce the levels of plasma cholesterol and triacylglycerol. It is also shown that phytosterol-fish oil esters lower non-HDL cholesterol ("bad cholesterol") but do not affect the level of HDL ("good cholesterol").

25 Table 1.

The effect of a phytosterol/fish oil esters containing diet on plasma total cholesterol and triacylglycerol levels in guinea pigs

		Total Cholesterol	Triacylglycerol
Group 1	Week 2	1.72 ± 0.38	0.92 ± 0.26
	Week 4	2.05 ± 0.20	0.87 ± 0.16
Group 2	Week 2	$1.22 \pm 0.10^*$	0.77 ± 0.22
	Week 4	$1.32 \pm 0.20^*$	$0.62 \pm 0.13^*$

Results are mean \pm S.D. of 8 guinea pigs per group. The baseline values for plasma total cholesterol and triacylglycerol were 1.28 ± 0.12 (mM) and 0.65 ± 0.11 (mM) respectively.

- 5 *Significantly lower than the corresponding value for Group 1 ($p < 0.05$; Bonferroni's Multiple Comparison Test).

Table 2.

The effect of a phytosterol/fish oil esters containing diet on lipoprotein metabolism in guinea pigs

		HDL Cholesterol	non-HDL Cholesterol
Group 1	Week 2	0.14 ± 0.03	1.58 ± 0.4
	Week 4	0.16 ± 0.06	1.90 ± 0.2
Group 2	Week 2	0.11 ± 0.04	$1.11 \pm 0.14^*$
	Week 4	0.16 ± 0.03	$1.17 \pm 0.23^*$

- 10 Results are mean \pm S.D. of 8 guinea pigs per group. The baseline values for HDL cholesterol and non-HDL cholesterol were 0.16 ± 0.07 (mM) and 1.14 ± 0.16 (mM) respectively.

*Significantly lower than the corresponding value for Group 1 ($p < 0.05$; Bonferroni's Multiple Comparison Test).

Example 3.

The effect of a phytosterol-fish oil ester-containing diet on plasma lipid levels in an obese rat model

The efficacy of a phytosterol-fish oil ester-containing diet to lower plasma triacylglycerol and cholesterol was studied in the JCR:La-cp (corpulent) rat, a genetic model of obesity (O'Brien and Russell, 1997). Animals of this strain, if homozygous for the autosomal recessive cp gene (cp/cp), are obese, insulin resistant, hyperinsulinemic, and highly hypertriglyceridemic. In addition the obese animals exhibit poor vascular responsiveness and develop ischemic lesions of the myocardium with age. Rats that are homozygous normal or heterozygous (+/?), are lean and metabolically normal. The effect of phytosterol-fish oil ester feeding was determined using obese (cp/cp) rats at 8 weeks of age, when the rats are clearly obese and fully insulin resistant. Lean littermates (+/?) of the obese animals were included in the study as benchmark for comparison. Obese animals were fed one of four diets: a control diet containing no added oil (Group 1); a control diet containing 2.6 g/kg canola (Group 2); or diets containing 0.5 or 2.6 g/kg phytosterol-fish oil ester (Group 3 and Group 4, respectively). The lean animals (Group 5) received the control without canola. The various test diets were fed for four weeks.

Preparation of the diets using standard rat chow (Rodent Diet 5001, PMI Nutrition International, St Louis, Mo) was essentially the same as described in Example 2. Phytosterol-fish oil ester was mixed with canola oil (5:1) and the oil mixture was added to the powdered diet at a concentration of 0.5 g/kg or 2.6 g phytosterol ester/kg diet,

which was then pelleted. Control diets contained no added oil or 2.6 g/kg canola oil. Food was stored in sealed plastic bags with nitrogen purging and maintained at 4°C. Fresh food was prepared each week.

5 Blood samples were collected from each animal at the start and after 4 weeks for determination of plasma lipids (total cholesterol, cholesterol esters, phospholipids, and triacylglycerols).

 Obese JCR-La rats exhibit marked hypertriglyceridemia
10 and elevated plasma cholesterol levels compared to their lean littermates (Group 1 or 2 versus Group 5; Table 3). There was a concentration-dependent effect of dietary phytosterol-fish oil esters on plasma lipid concentrations. The lower dose of 0.5 g phytosterol-fish oil ester/kg food had no impact on lipid
15 parameters in animals fed for 4 weeks (Group 3 versus Group 2 at 12 weeks; Table 3). However 2.6 g phytosterol-fish oil ester /kg food reduced triacylglycerol level from control levels by 51% (1.26 mM versus 2.59 mM in the control). Although this is a marked reduction, the animals are still strongly
20 hypertriglyceridemic (Group 4 versus Group 5). There was also a modest reduction of cholesterol levels in animals fed the high dose of phytosterol-fish oil ester (13% reduction in total cholesterol; 17% reduction in cholesterol esters). There was a tendency for phospholipid values to be reduced in phytosterol-
25 fish oil ester-fed animals but this did not reach statistical significance.

 The results show that phytosterol-fish oil esters decrease plasma triacylglycerol and cholesterol in obese JCR-La rats and that this occurs in a dose-dependent manner. The
30 reduction in triacylglycerol and cholesterol esters is

consistent with a substantial reduction in very low density lipoprotein (VLDL) particles through a decreased rate of VLDL production by the liver. These improvements in lipid profile might also be expected to have a beneficial effect on the

5 insulin-resistant state of these animals.

78162-20

Table 1. Whole serum lipid concentrations in high dose ON-1-treated male JCR-1A-cp rats

	Free Cholesterol	Cholesteryl esters	Total cholesterol	Phospholipids	Triacylglycerols
Initial values at 8 weeks of age:					
Group 1 (no oil control)	0.73 ± 0.11	1.19 ± 0.39	2.63 ± 0.49	2.19 ± 0.36	2.06 ± 1.19
Group 2 (oil control)	0.68 ± 0.10	1.89 ± 0.31	2.58 ± 0.40	2.01 ± 0.20	1.37 ± 0.63
Group 3 (0.5 mg/kg dose)	0.75 ± 0.12	2.01 ± 0.19	2.76 ± 0.30	2.35 ± 0.33	2.17 ± 1.11
Group 4 (2.6 mg/kg dose)	0.74 ± 0.09	1.94 ± 0.24	2.67 ± 0.33	2.28 ± 0.27	2.64 ± 0.84
Group 5 (lean control)	0.48 ± 0.06	1.31 ± 0.09	1.79 ± 0.12	1.01 ± 0.13	0.25 ± 0.16
Final values at 12 weeks of age:					
Group 1 (no oil control)	0.67 ± 0.06	1.58 ± 0.24	2.25 ± 0.29	1.92 ± 0.27	2.58 ± 0.93
Group 2 (oil control)	0.60 ± 0.09	1.61 ± 0.16	2.21 ± 0.23	1.87 ± 0.22	2.59 ± 0.58
Group 3 (0.5 mg/kg dose)	0.62 ± 0.14	1.55 ± 0.26	2.17 ± 0.37	1.90 ± 0.26	2.51 ± 0.71
Group 4 (2.6 mg/kg dose)	0.58 ± 0.06	1.34 ± 0.11**	1.92 ± 0.15*	1.66 ± 0.19	1.26 ± 0.72**
Group 5 (lean control)	0.34 ± 0.03	0.90 ± 0.04	1.24 ± 0.06	0.71 ± 0.04	0.17 ± 0.04

Values are mmol/l; mean ± S.D., 8 rats in each group. ** Significantly lower compared to group 2 (P<0.05).

References

- 1 Criqui, M.H. Triglycerides and cardiovascular disease: a focus on clinical trials. (1998) Eur Heart Journal 19 (Suppl A), A36-A39.
- 5 2 Grundy, S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. (1997) Circulation 95, 1-4.
- 3 Grundy, S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the Metabolic Syndrome. (1998) Am J Cardiol 81, 18B-25B.
- 10 4 Gotto Jr., A.M. Triglyceride: the forgotten risk factor. (1998) Circulation 97, 1027-1028.
- 5 Jeppeson, J., Hein, O.H., Suadicani, P. and Gyntelberg, F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. 15 (1998) Circulation 97, 1029-1036.
- 6 Franceschini, G. and Paoletti, R. Pharmacological control of hypertriglyceridemia. (1993) Cardiovasc Drugs Ther 7, 297-302.
- 7 Eisenberg, D. The importance of lowering cholesterol 20 in patients with coronary heart disease. (1998) Clin Cardiol 21, 81-84.
- 8 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival 25 Study (4S). (1994) Lancet 344, 1383-1389.
- 9 Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., MacFarlane, P.W., McKillop, J.H. and Packard, C.J. Prevention of coronary heart disease with pravastatin in 24

- men with hypercholesterolemia. (1995) N Engl J Med 333, 1301-1307.
- 10 Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., Brown, L., Warnica, J.W.,
5 Arnold, J.M.O., Wun, C., Davis, B.R. and Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. (1996) N Engl J Med 335, 1001-1009.
- 11 Heinemann, T., Kullak-Ublick, G.A., Pietruck, B. and
10 von Bergmann, K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption: comparison of sitosterol and sitostanol. (1991) Eur J Clin Pharmacol 40 (Suppl 1), S59-S63.
- 12 Ling, W.H. and Jones, P.J.H. Dietary phytosterols: a
15 review of metabolism, benefits and side effects. (1995) Life Sci 57, 195-206.
- 13 Jones, P.J.H., MacDougall, D.E., Ntanios, F. and Vanstone, C.A. Dietary phytosterols as cholesterol-lowering agents in humans. (1997) Can J Physiol Pharmacol 75, 217-227.
- 20 14 Vanhanen, H.T., Blomqvist, S., Ehnholm, C., Hyvonen, M., Jauhiainen, M., Torstila, I. and Miettinen, T.A. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. (1993) J Lipid Res ,
25 1535-1544.
- 15 Heinemann, T., Leiss, O. and von Bergmann, K. Effect of low-dose sitostanol on serum cholesterol in patients with hypercholesterolemia. (1986) Atherosclerosis 61, 219-223.

- 16 Miettinen, T.A. and Gylling, H. Regulation of
cholesterol metabolism by dietary plant sterols. (1999) Curr
Opin Lipidol 10, 9-14.
- 17 Vanhanen, H.T., Kajander, J., Lehtovirta, H. and
5 Miettinen, T.A. Serum levels, absorption efficiency, faecal
elimination and synthesis of cholesterol during increasing
doses of dietary sitostanol esters in hypercholesterolaemic
subjects. (1994) Clin Sci 1994 87, 61-67.
- 18 Leaf, A. and Weber, P.C. Cardiovascular effects of n-
10 3 fatty acids. (1988) N Engl J Med 318, 549-557.
- 19 Mishkel, G.J. and Cairns, J.A. Cardiovascular effects
of w-3 polyunsaturated fatty acids (fish oils). (1990)
Bailliere's Clin Haematol 3, 625-649.
- 20 Kinseella, J.E., Lokesh, B. and Stone, R.A. Dietary n-
15 3 polyunsaturated fatty acids and amelioration of
cardiovascular disease: possible mechanisms. (1990) Am J Clin
Nutr 52, 1-28.
- 21 Connor, S.L. and Connor, W.E. Are fish oils
beneficial in the prevention and treatment of coronary artery
20 disease? (1997) Am J Clin Nutr 66 (Suppl), 1020S-1031S.
- 22 Burr, M.L., Fehily, A.M., Gilbert, J.F., Rogers, S.,
Holliday, R.M., Sweetnam, P.M., Elwood, P.C. and Deadman, N.M.
Effects of changes in fat, fish, and fibre intakes on death and
myocardial reinfarction: diet and reinfarction trial. (1989) ;
25 Lancet 30, 757-761.
- 23 von Schacky, C., Angerer, P., Kothny, W., Theisen, K.
and Mudra, H. The effect of dietary omega-3 fatty acids on
coronary atherosclerosis: A randomized, double-blind, placebo-
controlled trial. (1999) Ann Intern Med 130, 554-562.

- 24 GISSI-Prevenzione Investigators. Dietary
supplementation with n-3 polyunsaturated fatty acids and
vitamin E after myocardial infarction: results of
the GISSI-Prevenzione trial. (1999) Lancet 354, 447-
5 455.
- 25 Harris, W.S. Fish oils and plasma lipid and
lipoprotein metabolism in humans: a critical review. (1989) J
Lipid Res 30, 785-807.
- 26 Carey, M.C., Small, D.M. and Bliss, C.M. Lipid
10 digestion and absorption. (1983) Annu Rev Physiol 45, 651-677.


CLAIMS:

1. A nutritional supplement comprising an ester formed between a sterol and an omega-3 fatty acid for lowering cholesterol and triglyceride levels in the bloodstream of a
5 subject.

2. The nutritional supplement according to claim 1, wherein the sterol is a phytosterol.

3. The nutritional supplement according to claim 1 or 2, wherein the omega-3 fatty acid has the formula:

10



wherein R^1 is a (C_3 - C_{40}) alkenylene group comprising at least one double bond.


15 4. The nutritional supplement according to claim 3, wherein R^1 has from 2 to 5 double bonds.

5. The nutritional supplement according to claim 4, wherein the omega-3 fatty acid is eicosapentaenoic acid 20:5 ω 3 (EPA).

20 6. The nutritional supplement according to claim 4, wherein the omega-3 fatty acid is docosahexaenoic acid 22:6 ω 3 (DHA).

7. The nutritional supplement according to any one of claims 1 to 6, wherein the sterol is a phytosterol.

8. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is stigmasterol.
9. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is sitosterol.
- 5 10. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is fucosterol.
11. The nutritional supplement according to any one of claims 1 to 7, wherein the sterol is fucostanol.
12. The nutritional supplement according to any one of
10 claims 1 to 7, wherein the sterol is β -sitostanol.
13. The nutritional supplement according to any one of claims 1 to 12, further comprising an edible additive.
14. A method of lowering cholesterol and triglyceride levels in the bloodstream of a subject, the method including
15 the step of administering to a subject an effective amount of a nutritional supplement comprising an ester formed between a sterol and an omega-3 fatty acid.
15. The method according to claim 14, wherein the omega-3 fatty acid is derived from fish oil.
- 20 16. The method according to claim 14 or 15, wherein the omega-3 fatty acid has the formula:



- 25 wherein R^1 is a $(\text{C}_3-\text{C}_{40})$ alkenylene group comprising at least one double bond.

17. The method according to claim 16, wherein R¹ has from 2 to 5 double bonds.
18. The method according to claim 17, wherein the omega-3 fatty acid is eicosapentaenoic acid 20:5 ω 3 (EPA).
- 5 19. The method according to claim 17, wherein the omega-3 fatty acid is docosahexaenoic acid 22:6 ω 3 (DHA).
20. The method according to any one of claims 14 to 19, wherein the sterol is a phytosterol.
21. The method according to any one of claims 14 to 20,
10 wherein the sterol is stigmasterol.
22. The method according to any one of claims 14 to 20, wherein the sterol is sitosterol.
23. The method according to any one of claims 14 to 20, wherein the sterol is fucosterol.
- 15 24. The method according to any one of claims 14 to 20, wherein the sterol is fucostanol.
25. The method according to any one of claims 14 to 20, wherein the sterol is β -sitostanol.
26. Use of a nutritional supplement comprising an ester
20 formed between a sterol and an omega-3 fatty acid, as defined in any one of claims 1 to 13, for lowering cholesterol and triglyceride levels in the bloodstream of a subject.
27. A foodstuff having a nutritional value enhanced by incorporation of the nutritional supplement according to any
25 one of claims 1 to 13.

28. Use of the nutritional supplement according to any one of claims 1 to 13 in the manufacture of a foodstuff.
29. A process for preparing the nutritional supplement as defined in any one of claims 1 to 13, which comprises the step
5 of reacting a sterol with an omega-3 fatty acid, or an ester thereof, in the presence of a base.
30. A process according to claim 29 wherein the base is a metal (C_1 - C_{10}) alkoxide.
31. A process according to claim 30, wherein the metal
10 (C_1 - C_{10}) is sodium methoxide.
32. A process according to claim 29, 30 or 31, which further comprises the step of precipitating unreacted sterol with a suitable non-polar solvent, and filtering off the precipitated unreacted sterol to leave a filtrate.
- 15 33. A process according to claim 32, wherein the non-polar solvent is hexane.
34. A process according to claim 32 or 33, which further comprises the step of extracting the filtrate with a suitable immiscible solvent to remove unreacted omega-3 fatty acid, or
20 an ester thereof, from the filtrate.
35. A process according to claim 34, wherein the immiscible solvent is methanol.
36. A process according to any one of claims 29 to 35, wherein the ester of the omega-3 fatty acid is a triglyceride
25 ester.
37. A process according to any one of claims 29 to 35, wherein the ester of the omega-3 fatty acid is an ethyl ester.

INTERNATIONAL SEARCH REPORT

Intern. nat. Application No.

PCT/CA 00/01011

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23L1/30 A61K31/575 C11C3/00 C07J9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A61K C11C C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	EP 0 897 970 A (UNILEVER PLC ;UNILEVER NV (NL)) 24 February 1999 (1999-02-24) claims 1,3-7; example 1 column 1, line 1-19 column 2, line 41 -column 3, line 43 -/-	1-3,7, 13,26-31 8-12, 32-37

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

*** Special categories of cited documents:**

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

10 January 2001

Date of mailing of the international search report

18 -01- 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentkan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Tallgren, A

INTERNATIONAL SEARCH REPORT

Intern. nat. Application No.

PCT/CA 00/01011

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHIMADA ET AL: "Enzymatic Synthesis of Steryl Esters of Polyunsaturated Fatty Acids" JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, US, AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN, vol. 76, no. 6, June 1999 (1999-06), pages 713-716, XP002132268 ISSN: 0003-021X	1-7
A	page 713, paragraph 3 page 714, paragraph 2 page 715, paragraph 6; table 3	1-13, 26-28
X	US 4 588 717 A (MITCHELL DAVID C) 13 May 1986 (1986-05-13) claims 1-4, 7, 9; examples 1-4 column 3, line 26-36 column 5, line 43 -column 6, line 38	1-4, 7-9, 13, 26-28
P, X	EP 1 004 594 A (HOFFMANN LA ROCHE) 31 May 2000 (2000-05-31) claims 1-7, 9, 10; examples 1, 7, 9, 10; table 2 page 2, line 3-15, 21-24 page 3, line 1-8 page 6, line 1-31, 39-46	1-9, 12, 13, 26-30
A		10, 11, 31-37
P, X	EP 0 982 315 A (MCNEIL PPC INC) 1 March 2000 (2000-03-01) claims 1, 2, 5-7, 9, 21; examples 6-9 page 2, line 45 -page 3, line 10, 30-39 page 5, line 15-23 page 6, line 16-50	1-4, 6, 7, 9, 12, 26-28

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/01011

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-25
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. nat. Application No

PCT/CA 00/01011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0897970 A	24-02-1999	CA 2245482 A US 6106886 A	22-02-1999 22-08-2000
US 4588717 A	13-05-1986	US 4705875 A	10-11-1987
EP 1004594 A	31-05-2000	AU 6065599 A BR 9905398 A CN 1256277 A JP 2000159792 A NO 995784 A	01-06-2000 08-08-2000 14-06-2000 13-06-2000 29-05-2000
EP 0982315 A	01-03-2000	US 5892068 A US 6147236 A AU 1316699 A AU 4450599 A BR 9900280 A BR 9903832 A CN 1245810 A CN 1251837 A EP 0982316 A HU 9900163 A HU 9902855 A JP 2000072794 A JP 2000072793 A PL 331161 A PL 335069 A	06-04-1999 14-11-2000 09-03-2000 09-03-2000 02-05-2000 19-09-2000 01-03-2000 03-05-2000 01-03-2000 28-07-2000 28-04-2000 07-03-2000 07-03-2000 28-02-2000 28-02-2000

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**